ProCE Banner Activity

Incorporating PARP Inhibitors for mCRPC: A Nursing Perspective

Clinical Thought

PARP inhibitors are an option for patients with metastatic castration-resistant prostate cancer and certain gene mutations. Read this expert commentary to learn about the evidence supporting PARP inhibitor therapy and gain insight into strategies to manage adverse events associated with PARP inhibitors.

Released: May 31, 2022

Expiration: May 30, 2023



Brenda Martone

Brenda Martone, MSN, ANP-BC, AOCNP

Nurse Practitioner
Northwestern Medicine
Chicago, Illinois


This activity is supported by educational grants from AstraZeneca; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Merck Sharp & Dohme Corp.



Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck Sharp & Dohme Corp.

Target Audience

NPs and PAs in oncology


Brenda Martone, MSN, ANP-BC, AOCNP has no relevant financial relationships to disclose.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.